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Background/Aims: Graves’ disease (GD) is caused by thyroid-stimulating hormone receptor (TSHR) and thyroid-
stimulating immunoglobulin (TSI). We used a recently introduced, technically enhanced TSI bioassay to assess its 
diagnostic value and determine the cut-off in patients in high iodine intake area. 
Methods: In a cross-sectional setting, we collected serum from 67 patients with untreated GD, 130 with GD under 
treatment, 22 with GD in remission, 42 with Hashimoto’s thyroiditis, 12 with subacute thyroiditis, 20 with postpartum 
thyroiditis, and 93 euthyroid controls. TSI was measured using the Thyretain
TM bioassay, which is based on Chinese 
hamster ovary cells transfected with chimeric TSHR (Mc4). TSI levels are reported as a specimen-to-reference ratio 
percentage (SRR%). 
Results: The TSI levels in patients with GD (either treated or not) were significantly higher than those of the remaining 
patients (p < 0.05). The new bioassay showed a sensitivity of 97.0% and a specificity of 95.9% with a cut-off value of 123.0 
SRR% for GD. A weak correlation was found between TSI and thyrotropin-binding inhibiting immunoglobulin (TBII) (rs = 
0.259, p = 0.03), but no correlation was found between TSI and tri-iodothyronine or free thyroxine. 
Conclusions: The Mc4-CHO bioassay showed comparable diagnostic value for GD with the conventional TBII assay. We 
propose a cut-off of 123.0 SRR% in areas where iodine intake is high. (Korean J Intern Med 2011;26:179-186)
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INTRODUCTION
Graves’ disease (GD) is caused by stimulating autoantib-
odies (Ab) to thyroid-stimulating hormone (also called 
thyrotropin) receptor (TSHR) [1]. TSHR-Abs can be 
measured either by bioassays or by thyrotropin-binding 
inhibiting immunoglobulin (TBII) assays [2]. TBIIs 
are quantified by receptor binding assays that measure 
their ability to inhibit TSHR binding by labeled TSH. 
These binding assays have sensitivities of 90-99% and 
specificities of 90-100% for diagnosing GD [3,4]. However, 
TBII assays cannot distinguish whether TSHR-Abs 
stimulate, block, or have no functional effect on the TSHR. 
GD bioassays detect cAMP production in different cell 
lines that express TSHR in response to stimulation with 
TSHR-simulating immunoglobulin (TSI), and can be used 
to determine whether pathogenic immunoglobulins are 
stimulative or inhibitory? TSIs in a patient’s serum result 
in increased production of cAMP, whereas TSHR-blocking 
antibodies (TB Abs) inhibit cAMP production after TSH 
stimulation in this type of bioassay [5-7]. However, the 
difficulties in maintaining cell lines, the lack of laboratory 
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automation, and longer time demands than binding assays 
still limit the use of these bioassays to specialized centers.
A new bioassay (Thyretain
TM) was recently introduced. 
This assay is based on Chinese hamster ovary (CHO) 
cells transfected with chimeric TSHR, which has amino 
acids 262-335 substituted with 73 amino acids from the 
rat luteinizing hormone (LH) receptor (Mc4) [8-10]. This 
substituted C-terminal area of TSHR contains epitopes for 
TB Abs. The Mc4 was designed to limit the effect of TB Abs 
that exist coincidentally with TSI in up to 25% of patients 
with GD and that can interfere with TSI measurements 
[11,12].
In this study, we evaluated the diagnostic value of this 
new assay and set cut-off values for diagnosing GD in 
Korea, where iodine intake is high.
METHODS
Patients
Samples were collected from patients that visited the 
outpatient clinic of the Department of Endocrinology and 
Metabolism at Samsung Medical Center (Seoul, Korea) 
between March 2010 and August 2010. We included 219 
patients with GD, 42 with Hashimoto’s thyroiditis, 12 
with subacute thyroiditis, 20 with painless/postpartum 
thyroiditis, and 93 euthyroid healthy controls. The 
criteria for GD were based on initially documented 
hyperthyroidism with or without Graves’ ophthalmopathy 
(GO) and increased uptake on technetium scintigraphy. 
The criteria for hyperthyroidism were clinical symptoms, 
increased serum concentrations of free thyroxine (T4), 
increased total triiodothyronine (T3), and decreased basal 
TSH. Patients with GD were divided into three groups 
according to their metabolic state and treatment history. 
The “untreated GD” group comprised patients who were 
not taking anti-thyroid medications or had been taking the 
medications for less than 2 weeks (n = 67); the “GD under 
treatment” group of patients were those that had been 
taking anti-thyroid medication for more than 2 weeks (n = 
130); and the “GD in remission” group comprised patients 
free of hyperthyroidism symptoms who were not taking 
any medication and who had normal TSH levels (n = 22). 
Hashimoto’s thyroiditis (n = 42) was diagnosed based on 
clinical hypothyroidism, sonography, and the presence of 
positive anti-thyroid peroxidase-autoantibodies (anti TPO 
Ab) and/or anti-thyroglobulin autoantibodies (anti TG 
Ab). We also included 12 patients with subacute thyroiditis 
in the study. Subacute thyroiditis was diagnosed based 
on clinical findings and a history of elevated erythrocyte 
sedimentation rates and low uptake on technetium 
scintigraphy. All patients with subacute thyroiditis had a 
history of severe neck pain. Fifteen patients with painless 
thyroiditis and five patients with postpartum thyroiditis 
(n = 20) were also included. The patients with painless 
thyroiditis had transient hyperthyroidism followed 
by hypothyroidism or recovery, whereas those with 
postpartum thyroiditis had the same disease course but 
only after pregnancy. Euthyroid healthy controls were 
subjects with a healthy euthyroid status and who were 
Table 1. Clinical data for patients in the various groups
Patients  No. Age (yr) Gender, 
female
Basal TSH 
(0.3-4.5 µIU/mL)
T3 
(70-190 ng/dL)
Free T4 
(0.6-1.7 ng/dL)
Anti-TPO 
antibody (+)
Thyroglobulin 
antibody (+)
Mc4 TSI 
(SRR%)
Untreated Graves’ disease 67 40.6 ± 13.1 53 (79.1) 0.02 ± 0.02  290.6 ± 149.1 3.0 ± 1.2 41 (61.2) 29 (43.3) 292.1 ± 109.4
Graves’ disease under 
   treatment
130 42.1 ± 13.4 94 (72.3)   3.1 ± 14.4 156.1 ± 94.0 1.4 ± 0.7 92 (70.8) 45 (34.6) 308.6 ± 148.3
Graves’ disease in 
   remission
22 43.1 ± 13.2 13 (59.1) 1.8 ± 1.5 113.6 ± 20.2 1.2 ± 0.2 15 (68.2)  7 (31.8) 147.6 ± 133.5
Hashimoto’s thyroiditis 42 50.4 ± 12.5 36 (85.7) 10.8 ± 27.0 102.6 ± 13.9 1.1 ± 0.4 40 (95.2) 36 (85.7) 67.8 ± 30.1
Subacute thyroiditis 12 44.2 ± 11.6 10 (83.3) 3.4 ± 9.8 147.7 ± 64.6 1.7 ± 0.8  2 (16.7)   2 (16.7) 39.3 ± 14.8
Postpartum or painless
   thyroiditis
20 39.4 ± 12.4 17 (85.0) 21.8 ± 64.9 141.1 ± 66.6 1.7 ± 0.9 13 (65.0) 12 (60.0) 62.3 ± 66.6
Euthyroid healthy controls 93 50.2 ± 11.9 72 (77.4) 2.2 ± 1.2 109.9 ± 18.7 1.2 ± 0.2        0 (0)          0 (0) 41.1 ± 15.7
Values are presented as mean ± SD or number (%).
TSH, thyroid stimulating hormone; T3, triiodothyronine; T4, thyroxine; TPO, thyroid peroxidase; TSI, thyroid-stimulating immunoglobulin; 
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negative for both the anti TPO Ab and anti TG Ab (n = 
93). The laboratory findings of the study subjects are 
summarized in Table 1. Informed consent was obtained 
from all patients, and the study was approved by the 
Institutional Review Board of Samsung Medical Center.
TSI bioassay 
Serum TSI levels were measured with the Thyretain
TM 
(Diagnostic Hybrids Inc., Athens, OH, USA) bioreporter 
assay, according to the manufacturer’s instructions. Each 
sample was assayed in triplicate, and the mean values 
were used for analysis. 
This bioreporter assay is specific to stimulating TSHR-
Ab activation because of the chimeric receptor (Mc4) 
expressed on the surface of CHO cells. In Mc4, the 
C-terminus of TSHR (amino acids 262-335) has been 
substituted with amino acids 261-329 of the rat LH-
choriogonadotropin (LH-CG) receptor [8]. This substituted 
C-terminal area of TSHR contains epitopes for TB Abs; 
Mc4 was designed to reduce the interfering effect of TB 
Abs when measuring TSIs by eliminating the epitope 
region of TSHR using TB Abs.
The Mc4 gene was transfected into CHO cells with a 
luciferase reporter gene. When TSIs bind to Mc4 receptors 
on Mc4-CHO cells, the resulting signal cascades stimulate 
increased production of intracellular cAMP. The cAMP 
induces activation of a promoter containing a cAMP-
regulated enhancer upstream of the luciferase gene. 
Luciferase activity, measured as relative light units, can 
be determined in cell lysates with a luminometer after an 
enzymatic reaction containing luciferin. 
Briefly, on day 1, the inner 48 wells of a Corning 96-
well clear, flat-bottom, black plate were treated with a 
cell-attachment solution and seeded with thawed Mc4-
CHO cells diluted in plating medium (all provided by 
the manufacturer). Plates were then incubated for 15-18 
hours in a humidified 5% CO2 37°C incubator. On day 2, 
we checked that all wells of the plate were confluent by 
assessing whether a monolayer of healthy-looking Mc4-
CHO cells was present. Then the wells were washed with 
37°C warmed reaction buffer, and 100 µL reaction buffer 
was added to each well. After adding 100 µL sample 
serum (serum:reaction buffer = 1:10) to each well, the 
plate was incubated at 37°C in 5% CO2 for 3 hours. After 
removing all solutions from the well, 75 µL cell lysis 
solution containing luciferase substrate was added to each 
well. After 10 minutes incubation at room temperature, 
the plate was read on a Veritas Microplate Luminometer 
(Turner Biosystems, Crailsheim, Germany). All assay 
procedures were completed within a 24-hour period.
The results of the Mc4-CHO bioassay are reported 
as specimen-to-reference ratio percentages (SRR%), 
calculated as follows: SRR% = (mean TSIspecimen / mean 
TSIreference) × 100. The mean TSIspecimen is the mean of 
triplicate luminescence measurements in the wells 
containing serum, and the mean TSIreference is the mean 
of triplicate measurements of the wells containing a 
reference provided by the manufacturer, which is bovine 
TSH at a concentration of 0.1 IU/mL. 
Intra- and inter-assay precision for the Mc4-CHO 
bioassay was calculated from four different serum samples 
(high-positive, medium-positive, low-positive, and 
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Figure 1. The intra-assay (A) and inter-assay (B) coefficient of variation (CV) for precision in the high-positive, medium-positive, low-
positive, and negative control sets. 
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negative) by calculating the coefficient of variation (CV% = 
SDeach control / Meaneach control × 100). 
Conventional binding assay (TBII) and thyroid 
function tests
TBII was measured using the human TRAK RIA kit 
(Brahms AG, Hennigsdorf, Germany) with a suggested 
cut-off value of 1.5 IU/L.
The serum concentrations of TSH, total T3, and 
free T4 were measured using a commercially available 
radioimmunoassay TSH IRMA kit (Immunotech Inc., 
Praha, Czech Republic; reference range 0.3 to 4.5 µIU/
mL), a total T3 RIA kit (Immunotech; reference range, 
76 to 190 ng/dL), and a free T4 RIA kit (Immunotech) 
(reference range, 0.64 to 1.72 ng/dL).
Anti TG Ab (reference range, 0 to 60 U/mL) and anti 
TPO Ab (reference range, 0 to 60 U/mL) were measured 
with anti-Tgn (Brahms AG) and anti-TPOn (Brahms AG), 
respectively. 
Statistical analysis
Differences in continuous variables between groups 
were tested by independent-sample t tests. Differences 
between categorical variables within groups were 
tested with the chi-square test or Fisher’s exact test, as 
appropriate. Correlation analyses were performed using 
Spearman’s rank correlation coefficient.
A receiver operating characteristic (ROC) curve analysis 
was performed to obtain the optimal cut-off for positivity 
in the Mc4-TSI bioassay. The sensitivity and specificity 
were estimated from the ROC curves. A p value < 0.05 was 
considered statistically significant. 
RESULTS
Diagnostic value of the Mc4-TSI bioassay
The intra-assay CVs were 3.0% for the high-positive 
control set (496 SRR%), 5.0% for the medium-positive 
control set (212 SRR%), 4.4% for the low-positive control 
set (144 SRR%), and 6.8% for the negative control set 
(41 SRR%), with mean TSI values of 496, 212, 144, and 
41%, respectively. The inter-assay CVs were 10.8, 7.0, 6.6, 
and 19.5% with mean TSI values of 444, 199, 141, and 36 
SRR%, respectively (Fig. 1). To obtain the optimal decision 
threshold level for diagnosing GD, an ROC analysis was 
performed on 67 patients with untreated GD and on 74 
patients with Hashimoto’s thyroiditis, subacute thyroiditis, 
or painless/postpartum thyroiditis. The area under the 
curve for the Mc4-CHO bioassay was 0.97 (95% confidence 
interval, 0.94 to 1.00), and the optimal cut-off was set at 
100-specificity
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Figure 2. Receiver operating curve analysis of Mc4 thyroid-
stimulating hormone receptor and thyroid-stimulating 
immunoglobulin data from 141 patients (67 with untreated 
Graves’ disease, 42 with Hashimoto’s thyroiditis, 12 with 
subacute thyroiditis, and 20 with painless/postpartum 
thyroiditis patients). 
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Figure 3. Distribution of serum Mc4 thyroid-stimulating 
hormone receptor (TSHR) and thyroid-stimulating 
immunoglobulin (TSI) values in each study group. The mean 
TSIs of each group of patients with Graves’ disease (GD) 
(untreated, in treatment, and in remission) were significantly 
higher than those with Hashimoto’s thyroiditis, subacute 
thyroiditis, postpartum/painless thyroiditis, and healthy 
euthyroid controls (p < 0.01). The line for each group indicates 
the mean value. The dotted line represents the cut-off value of 
123.0 specimen-to-reference ratio percentage (SRR%).Lee JI, et al. TSH receptor autoantibody bioassay for Graves’ disease    183
123.0 SSR% with 97.0% sensitivity and 95.9% specificity 
for diagnosing GD (Fig. 2).
 
Serum TSI measurements in each study group
The distributions of serum TSI levels in each study 
group, as measured by the Mc4-TSI bioassay, are shown in 
Fig 3. 
Of 67 untreated patients with GD, 65 (97.0%) had 
positive TSI bioassay results. In contrast, of 42 patients 
with Hashimoto’s thyroiditis, only 1 (2.4%) had a positive 
result, while of 20 patients with painless/postpartum 
thyroiditis, 2 (10%) tested positive using the new bioassay. 
All patients with subacute thyroiditis (n = 12) had negative 
results on the Mc4-TSI bioassay. None of the euthyroid 
healthy controls (n = 93) were positive using the new TSI 
bioassay. 
The TSI values (mean and SD) measured by the Mc4-
CHO bioassay for patients with untreated GD, GD under 
treatment, GD in remission, Hashimoto’s thyroiditis, 
subacute thyroiditis, postpartum/painless thyroiditis, 
and euthyroid healthy controls were 292.1 (109.4), 308.6 
(148.3), 147.6 (133.5), 67.8 (30.1), 39.3 (14.8), 62.3 (66.6), 
and 41.1 (15.7) SRR%, respectively. The TSI levels in 
treated and untreated patients with GD were significantly 
higher (p < 0.01) than those in patients with Hashimoto’s 
thyroiditis, subacute thyroiditis, postpartum/painless 
thyroiditis, or the healthy euthyroid controls (Table 1).
Correlation between TSI and TBII 
The Mc4-TSI values of untreated patients with GD were 
plotted against the TBII, total T3, and free T4 values. A 
weak correlation was found between TSI and TBII (rs = 
0.259, p = 0.03). No correlation was found between Mc4-
TSI and total T3 or free T4 (Fig. 4).
When we compared the positivity of the TSHR Abs in 
the conventional TBII test and the Mc4-TSI bioassay, there 
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Figure 4. Correlation of Mc4 thyroid-stimulating hormone 
receptor (TSHR) and thyroid-stimulating immunoglobulin (TSI) 
values with thyrotropin-binding inhibiting immunoglobulin 
(TBII) (A), total triiodothyronine (T3) (B), and free thyroxine (T4) 
(C) values in 67 patients with untreated Graves’ disease. TSI is 
represented by specimen-to-reference ratio percentage (SRR%). 
Correlation coefficients and p values are shown in each figure.
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was no significant difference between these two tests 
within the study groups (Table 2). 
DISCUSSION
Our results show that the Mc4-TSI bioassay based on 
Mc4-CHO cells expressing chimeric TSH receptors, which 
was designed to interact with stimulating but not blocking 
TSHR-Abs, had good diagnostic value (sensitivity, 97.0%; 
specificity, 95.9%) with a cut-off of 123.0 SRR%. This 
diagnostic value is similar to the more widely available 
binding assay that measures TBII but does not provide 
information about the TSHR-Ab function.
Our study had several limitations. First, it was a cross-
sectional study that focused on the diagnostic value and 
the appropriate cut-off value for the new Mc4-TSI bioassay 
in patients from Korea, an area where iodine intake is high. 
Thus, we did not investigate the clinical implications of 
the TSI bioassay, such as the response to therapy, disease 
course, or prediction of relapses. Second, the diagnostic 
sensitivity (98.5%) of the conventional TBII assay for GD 
was slightly higher than that reported in another study 
[2]. Selection bias during enrollment of patients with GD 
may have influenced the results, because there was a 
tendency to enroll patients with a definite diagnosis of GD 
in this trial. Nevertheless, Mc4-TSI showed comparable 
diagnostic value to conventional TBII. Third, we could 
not compare the chimeric TSH receptor (Mc4) based 
bioassays, which use the human TSH receptor, due to kit 
unavailability. Future studies comparing the diagnostic 
and prognostic values between these bioassays are 
warranted. Finally, the clinical symptoms of GD were 
recorded only with regard to their presence or absence 
and were not graded; thus, we were not able to perform 
a correlation analysis between the severity of clinical 
symptoms and Mc4-TSI. Furthermore, the presence of eye 
disease was not evaluated by an ophthalmologist because 
the coexistence of clinical GO is uncommon in Korea [13]. 
Early bioassays used human thyrocytes or Fisher rat 
thyroid line-5 cells, and cAMP production was measured 
by radioisotopes; therefore, these assays were technically 
demanding. Later, the introduction of cell lines that stably 
expressed both TSHR and a luciferase reporter gene 
simplified the bioassays and made them more reliable, but 
it still took 3 days to measure TSI [5,14,15]. TB Abs that 
target functional epitopes on the C-terminal of the TSHR 
extracellular domain and that block TSHR function may 
exist coincidentally with TSI in 25.6% of patients with GD 
[11,12,16]. These TB Abs can block TSI as well as TSH and 
interfere with measurements of the stimulative  activity of 
TSHR autoantibodies; therefore, a C-terminal-substituted 
chimeric TSHR was designed to exclude the effect of TB 
Abs present in the blood in one quarter of all patients with 
GD [8]. The Thyretain
TM assay uses CHO cells transfected 
with a chimeric version of the TSHR (Mc4) receptor; 
residues 262-335 of TSHR have been substituted with 73 
amino acids from the LH-CG receptor segment to improve 
TSI bioassay sensitivity in patients with GD. The test time 
for this bioassay has also been reduced from 3 days to less 
than 24 hours, with an improved CV. Nevertheless, this 
bioassay still takes much longer to perform than the widely 
available TBII assay, and laboratory automation remains 
challenging to establish, because a cell culture system is 
needed.
Lytton et al. [9] reported that the Mc4-TSI test has better 
sensitivity and specificity than TBII (97% vs. 77% and 89% 
vs. 43%, respectively) for detecting 155 GO cases among 
Table 2. Comparison of the Mc4-TSI bioassay and TBII binding assay within each study group
Patients TBII ≥ 1.5 IU/L Mc4-TSI ≥ 123% p value
Untreated Graves’ disease    66/67 (98.5)    65/67 (97.0) NS
Graves’ disease under treatment 118/130 (90.8)   112/130 (83.8) NS
Graves’ disease in remission      5/22 (22.7)     10/22 (36.4) NS
Hashimoto’s thyroiditis    4/42 (9.5)     1/42 (2.4) NS
Subacute thyroiditis 0/12 (0)    0/12 (0)
Postpartum/painless thyroiditis    1/20 (5.0)   2/20 (10) NS
Euthyroid healthy controls 0/93 (0)  0/93 (0)
 Values are presented as number (%).
TSI, thyroid-stimulating immunoglobulin; TBII, thyrotropin-binding inhibiting immunoglobulin; NS, not significant.Lee JI, et al. TSH receptor autoantibody bioassay for Graves’ disease    185
200 patients with GD from Germany. They used the cut-
off suggested by the company, which was 140 SSR%. 
However, most (156/200, 76%) of the patients with GD in 
their study had already been treated with drugs (123/200, 
61.5%), thyroidectomy (18/200, 9%), or radioiodine 
(11/200, 5.5%), and the reported diagnostic value was for 
GO, not for GD. Furthermore, the iodine intake in Korea 
is very high (479 µg/day), and the average amount of urine 
iodine excreted is 674 µg/g Cr [17,18]. These levels are 
much higher than those reported in Germany, where the 
median intake of daily iodine is around 100 µg/day [19]. 
Thus, the composition of autoantibodies (stimulating and 
blocking TSHR), the TSI cut-off value, and the prevalence 
of GO are likely to differ according to country. Therefore, 
we assessed the diagnostic value of Mc4-TSI for GD and 
set the cut-off at 123.0 SRR% to distinguish between GD 
and various functional thyroid diseases in Korea where 
iodine intake is high. At this cut-off level, the Mc4-TSI 
diagnostic value was similar to that of the more widely 
used TBII binding assay (sensitivity, p > 0.05, 97% vs. 
98.5%; specificity, p > 0.05, 95.9% vs. 94.3%, respectively). 
Kamijo et al. [10] reported that the Mc4-TSI bioassay 
is superior to the conventional bioassay based on porcine 
thyroid cells for diagnosing 103 patients with GD from 
Japan (sensitivity, p < 0.05, 95.1% vs. 89.3%; specificity, p 
< 0.05, 96.0% vs. 86.9%, respectively). However, they did 
not report the TSI levels according to TBII. The diagnostic 
values were similar to those reported in our study, and 
their cut-off value of 128.0 SRR% was similar to our cut-
off value of 123.0 SRR%, indicating that the new Mc4-
CHO bioassay has reliable diagnostic value in areas where 
iodine intake is high, such as Korea and Japan.
In conclusion, the new Thyretain
TM bioassay, based 
on an Mc4 chimeric TSHR, had comparable diagnostic 
value to the widely used TBII binding assay for GD. 
Furthermore, we propose a cut-off of 123.0 SRR% for 
areas where iodine intake is high. Future research on the 
response of GD to various treatment modalities, including 
anti-thyroid drugs, as well as disease prognoses, relapses, 
and implications of TSI for pregnancy using this new 
bioassay are clearly warranted.
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